#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3190	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2419	389.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1823	1823	T	455	T	380	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3190	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2419	389.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1557	1557	C	525	C,T	406,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3190	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2419	389.3	0	HET	.	.	.	A69G,C	.	69	69	A	442	442	A	404	A,G,C	241,109,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5220	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3856	403.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1883	1883	A	409	A,T	331,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5220	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3856	403.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2517	2517	C	455	C	369	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5220	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3856	403.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2591	2591	A	456	A	361	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5220	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3856	403.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	3143	3143	C	439	C	349	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	539	512	folP	852	852	99.88	folP.l6.c4.ctg.1	1781	85.3	0	.	p	.	0	E151K	NONSYN	451	453	GAA	907	909	AAA	114;113;113	A;A;A,G	91;92;90,1	.	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	539	512	folP	852	852	99.88	folP.l6.c4.ctg.1	1781	85.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1138	1140	AGC	102;102;102	A;G;C	85;86;83	folP.WHO_G_01367c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1010	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3864	78.2	1	SNP	p	S91F	0	.	.	271	273	TCC	820	822	TCC	88;88;88	T;C;C	70;70;73	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1010	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3864	78.2	1	SNP	p	D95N	0	.	.	283	285	GAC	832	834	GAC	83;83;83	G;A;C	68;70;68	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1010	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3864	78.2	1	SNP	p	D95G	0	.	.	283	285	GAC	832	834	GAC	83;83;83	G;A;C	68;70;68	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	442	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1520	86.8	1	SNP	p	G45D	0	.	.	133	135	GGC	596	598	GGC	127;127;127	G;G;C	103;103;104	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	226	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1305	51.8	0	.	n	.	0	A197.	DEL	197	197	A	662	662	A	103	A	80	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1110	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3318	99.8	1	SNP	p	D86N	0	.	.	256	258	GAC	681	683	GAC	132;132;132	G;A;C	108;109;111	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1110	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3318	99.8	1	SNP	p	S87R	0	.	.	259	261	AGT	684	686	AGT	133;133;133	A;G;T,G	108;114;105,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1110	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3318	99.8	1	SNP	p	S87W	0	.	.	259	261	AGT	684	686	AGT	133;133;133	A;G;T,G	108;114;105,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1110	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3318	99.8	1	SNP	p	S87I	0	.	.	259	261	AGT	684	686	AGT	133;133;133	A;G;T,G	108;114;105,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1110	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3318	99.8	1	SNP	p	S88P	0	.	.	262	264	TCC	687	689	TCC	133;134;135	T;C;C	107;112;115	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	946	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3015	94.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1728	1730	GGC	127;127;127	G;G;C	108;105;104	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	826	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2849	86.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1496	1498	GCA	119;119;119	G,A;C,A;A,C	91,1;92,1;92,1	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	826	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2849	86.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1499	1501	ATC	119;119;120	A;T;C	94;92;96	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	826	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2849	86.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1511	1513	GTG	122;120;120	G;T;G	95;95;94	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	826	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2849	86.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1511	1513	GTG	122;120;120	G;T;G	95;95;94	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	826	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2849	86.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2015	2017	ACC	96;94;94	A,C;C;C	79,1;78;81	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	826	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2849	86.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2069	2071	GCG	99;100;98	G,A;C;G,C	81,2;77;78,1	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	826	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2849	86.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2069	2071	GCG	99;100;98	G,A;C;G,C	81,2;77;78,1	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	826	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2849	86.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2192	2194	GGC	96;96;97	G,C;G;C	79,1;74;79	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	826	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2849	86.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2201	2203	GGC	97;97;97	G;G;C	78;80;79	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	826	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2849	86.8	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2219	2221	CTG	97;97;96	C;T;G	85;79;83	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1120	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3437	97.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1848	1850	CCG	98;99;99	C,T;C;G	76,2;81;78	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	580	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2267	76.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	859	859	C	72	C	61	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	696	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1841	111.6	0	.	p	.	0	N38E	NONSYN	112	114	AAT	476	478	GAA	133;134;134	G;A;A	111;113;114	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	696	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1841	111.6	0	.	p	.	0	N134D	NONSYN	400	402	AAT	764	766	GAT	154;154;156	G;A,C;T	123;118,1;123	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	696	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1841	111.6	0	.	p	.	0	P175S	NONSYN	523	525	CCA	887	889	TCA	156;156;157	T;C;A,G	117;123;122,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	696	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1841	111.6	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1016	1018	GTC	162;161;162	G;T;C	128;129;134	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	696	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1841	111.6	1	SNP	p	G120K	1	.	.	358	360	AAG	722	724	AAG	152;152;152	A;A;G,A	119;125;121,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	696	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1841	111.6	1	SNP	p	A121D	1	.	.	361	363	GAC	725	727	GAC	152;152;153	G;A;C	124;119;125	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	696	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1841	111.6	1	SNP	p	D121N	0	.	.	361	363	GAC	725	727	GAC	152;152;153	G;A;C	124;119;125	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	2556	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5283	144.7	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2179	2181	AAT	140;140;140	A,C;A,C;T	116,1;115,1;116	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	386	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1418	81.7	1	SNP	p	V57M	1	.	.	169	171	ATG	693	695	ATG	162;162;163	A;T;G	132;133;131	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
